Closed |
S0701 |
Gastric Cancer Prevention |
6/16/2009 |
6/30/2010 |
100% |
|
Published
|
Closed |
S0910 |
Cytarabine/Clofarabine +/- Epratuzumab for Relapsed/Refractory B-cell ALL |
8/15/2010 |
7/1/2012 |
100% |
|
Published
|
Closed |
S0806 |
Phase I/II DLBCL Vorinostat with R-CHOP |
11/15/2010 |
10/1/2013 |
100% |
|
Published
|
Closed |
S0925 |
New Hormone-Sensitive Metastatic PCa, Androgen Deprivation +/- IMC-A12, Ph II |
12/15/2010 |
12/1/2012 |
100% |
|
Published
|
Closed |
S1005 |
Ph II MK-2206 gastric and GEJ |
1/1/2011 |
5/1/2013 |
100% |
|
Published
|
Closed |
S1007 |
ADJUVANT: Phase III Randomized Endocrine Therapy +/- Chemo according to RS |
1/15/2011 |
|
100% |
|
|
Closed |
S0931 |
Adjuvant Renal Cell, Everolimus vs Placebo, Ph III |
4/1/2011 |
9/15/2016 |
100% |
|
|
Closed |
S1011 |
Muscle-Invasive Bladder Ca, Std vs Ext PLND, Ph III |
8/1/2011 |
4/15/2017 |
100% |
|
|
Closed |
S1001 |
Phase II Early Stage DLBCL |
7/18/2011 |
6/1/2016 |
100% |
|
|
Closed |
S0927 |
Ph III Omega-3 fatty acid/placebo Breast Cancer |
2/1/2012 |
2/1/2013 |
100% |
|
Published
|
Closed |
S1108 |
Phase II MLN8237 in Peripheral T-Cell NHL |
10/28/2011 |
6/6/2013 |
100% |
|
Published
|
Closed |
S1119 |
Water Contamination Study |
12/2/2011 |
8/5/2013 |
100% |
|
Published
|
Closed |
S1008 |
Physical activity & dietary change weight loss in breast & colorectal survivors Ph II |
3/1/2012 |
7/1/2014 |
100% |
|
|
Closed |
S1117 |
Rando PII Aza vs. Aza/Len vs. Aza/Vorin for High Risk MDS and CMML |
3/1/2012 |
11/14/2014 |
100% |
|
Published
|
Closed |
S1105 |
Text Messaging Study |
3/27/2012 |
9/15/2013 |
100% |
|
|
Closed |
S1115 |
Rando Phase II of AZD-6244 add MK-2206 vs mFOLFOX in Pts with Met Pancreatic Cancer After Chemo |
8/15/2012 |
5/15/2014 |
100% |
|
Published
|
Closed |
S1211 |
PII Optimal Induction for HRMM |
10/12/2012 |
|
100% |
|
|
Closed |
S1207 |
Ph. III Randomized, Everolimus in high risk, hormone receptor positive, HER2 negative patients. |
9/3/2013 |
5/1/2019 |
100% |
|
|
Closed |
S1216 |
Metastatic Prostate Cancer, Phase III ADT+TAK-700 vs. ADT+Bicalutamide |
3/1/2013 |
7/15/2017 |
100% |
|
|
Closed |
S1202 |
Ph III Study of Duloxetine for AI-associated musculoskleteal symptoms for Early Stage BrCa |
5/15/2013 |
10/1/2015 |
100% |
|
Published
|